/ /

  • linkedin
  • Increase Font
  • Sharebar

    Study explores ranibizumab as treatment for ROP



    The efficacy analyses showed both anti-VEGF agents were effective in reducing the activity of ROP—improvements were noted in vascular tortuosity, dilatation, and tunica vasculosa lentis.

    The rate of recurrence (defined as conditions requiring further treatment) was higher in the ranibizumab group than in eyes treated with bevacizumab (26% vs. 10%). The difference in recurrence rates did not achieve statistical significance, although the study may have been underpowered to detect a difference.

    The interval between treatment and recurrence was also not significantly different between the ranibizumab and bevacizumab groups.

    The retina re-attached in all bevacizumab eyes and in 26 (96%) of the ranibizumab-treated eyes.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results